GoodRx appoints Scott Wagner as director, co-chair; Simon Patterson resigns from board

GoodRx Holdings, Inc.

Scott Wagner appointed Class II director, Chair of Compensation Committee, and Co-Chair of the Board effective Jan 21, 2025.
Wagner previously served as GoodRx Interim CEO from April 2023 to January 2025.
Simon Patterson resigned as director, not due to any disagreement with Company or management.
Vacancy filled by Silver Lake Stockholders exercising board designation rights; Wagner appointed.
Wagner receives standard non-employee director compensation: initial RSU award of $420,000 and pro-rated annual RSU of $85,699.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Scott Wagner

Class II Director

GDRX · GoodRx Holdings, Inc.

Effective: 2025-01-21
Filed: January 22, 2025, 6:59 PM ET

On January 21, 2025, the Board of Directors (the “Board”) of GoodRx Holdings, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Scott Wagner as a Class II director of the Company.

Departed

Simon Patterson

Director

GDRX · GoodRx Holdings, Inc.

Effective: 2025-01-21
Successor: Scott Wagner
Filed: January 22, 2025, 6:59 PM ET

On January 21, 2025, Simon Patterson resigned as a member of the Board and as a member of the Board’s Nominating and Corporate Governance Committee and Innovation Committee.

Appointed

Scott Wagner

Co-Chair of the Board

GDRX · GoodRx Holdings, Inc.

Effective: 2025-01-21
Filed: January 22, 2025, 6:59 PM ET

The Board also appointed Mr. Wagner as the Chair of the Board’s Compensation Committee, and appointed Mr. Wagner as a Co-Chair of the Board, to serve in such role together with the existing Chair (now to be referred to as Co-Chair), Trevor Bezdek.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Scott Wagner was appointed as Class II Director at GoodRx Holdings, Inc..

Action: appointed
Role: Class II Director

Exact text from the filing

On January 21, 2025, the Board of Directors (the “Board”) of GoodRx Holdings, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Scott Wagner as a Class II director of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Simon Patterson resigned as Director at GoodRx Holdings, Inc..

Action: resigned
Role: Director

Exact text from the filing

On January 21, 2025, Simon Patterson resigned as a member of the Board and as a member of the Board’s Nominating and Corporate Governance Committee and Innovation Committee.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Scott Wagner was appointed as Co-Chair of the Board at GoodRx Holdings, Inc..

Action: appointed
Role: Co-Chair of the Board

Exact text from the filing

The Board also appointed Mr. Wagner as the Chair of the Board’s Compensation Committee, and appointed Mr. Wagner as a Co-Chair of the Board, to serve in such role together with the existing Chair (now to be referred to as Co-Chair), Trevor Bezdek.

View on SEC.gov

GoodRx Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001809519-25-000015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.